Galecto Inc
GLTO
查看详细走势图
27.170USD
+1.170+4.50%
收盘 12/19, 16:00（美东）报价延迟15分钟
36.06M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.50%
5天
-15.09%
1月
+56.60%
6月
+706.23%
今年开始到现在
+484.30%
1年
+478.09%
查看详细走势图
TradingKey Galecto Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Galecto Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
强力买入
评级
36.000
目标均价
+39.91%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Galecto Inc亮点
亮点风险
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Galecto Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Galecto Inc简介
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
公司代码GLTO
公司Galecto Inc
CEOSchambye (Hans T)
网址https://galecto.com/
常见问题
Galecto Inc(GLTO)的当前股价是多少？
Galecto Inc(GLTO)的当前股价是 27.170。
Galecto Inc的股票代码是什么？
Galecto Inc的股票代码是GLTO。
Galecto Inc股票的52周最高点是多少？
Galecto Inc股票的52周最高点是33.600。
Galecto Inc股票的52周最低点是多少？
Galecto Inc股票的52周最低点是2.010。
Galecto Inc的市值是多少？
Galecto Inc的市值是36.06M。
Galecto Inc的净利润是多少？
Galecto Inc的净利润为-21.44M。
现在Galecto Inc(GLTO)的股票是买入、持有还是卖出？
根据分析师评级，Galecto Inc(GLTO)的总体评级为--，目标价格为36.000。
Galecto Inc(GLTO)股票的每股收益（EPS TTM）是多少
Galecto Inc(GLTO)股票的每股收益（EPS TTM）是-12.100。
相关品种
